Last quarter (Q ), Ayala Pharmaceuticals's total revenue was $91.00K, a decrease of -85.44% from the same quarter last year. In Q, Ayala Pharmaceuticals's net income was $-10.19M. See Ayala Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 1.73M	$ 3.51M	$ 3.71M	$ 2.33M	$ 0.00
Cost of Revenue	$ 1.64M	$ 3.51M	$ 3.71M	$ 1.28M	$ 0.00
Gross Profit	$ 90.00K	$ 0.00	$ 0.00	$ 1.05M	$ 0.00
Operating Expense	$ 37.63M	$ 39.22M	$ 29.78M	$ 18.76M	$ 9.04M
Operating Income	$ -37.54M	$ -39.22M	$ -29.78M	$ -17.71M	$ -9.04M
Net Non Operating Interest Income Expense	$ -224.00K	$ -260.00K	$ 56.00K	$ 225.00K	$ 448.00K
Other Income Expense	-	-	-	-	-
Pretax Income	$ -37.77M	$ -39.48M	$ -29.72M	$ -17.49M	$ -8.59M
Tax Provision	$ 708.00K	$ 776.00K	$ 425.00K	$ 306.00K	$ 286.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -38.47M	$ -40.25M	$ -30.15M	$ -17.79M	$ -8.87M
Basic EPS	$ -2.52	$ -2.80	$ -3.06	$ -2.07	$ -1.31
Diluted EPS	$ -2.52	$ -2.80	$ -3.06	$ -2.07	$ -1.31
Basic Average Shares	$ 61.30M	$ 14.40M	$ 9.86M	$ 8.58M	$ 6.77M
Diluted Average Shares	$ 61.30M	$ 14.40M	$ 9.86M	$ 8.58M	$ 6.77M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	$ -2.07	$ -1.31
Reported Normalized Diluted E P S	-	-	-	$ -2.07	$ -1.31
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 39.27M	$ 42.72M	$ 33.48M	$ 20.05M	$ 9.04M
Net Income From Continuing And Discontinued Operation	$ -38.47M	$ -40.25M	$ -30.15M	$ -17.79M	$ -8.87M
Normalized Income	$ -38.47M	$ -40.25M	$ -30.15M	$ -17.79M	$ -8.87M
Interest Expense	$ 156.00K	$ 260.00K	-	-	-
EBIT	$ -37.54M	$ -39.22M	$ -29.78M	$ -17.71M	$ -9.04M
EBITDA	$ -37.39M	$ -39.05M	$ -29.59M	$ -17.56M	$ -8.99M

Currency in USD

Ayala Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing